Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases

The prevalence of prostate cancer continues to increase worldwide. The effectiveness of androgen deprivation therapy for advanced prostate cancer has a time limit, after which castration resistance and disease progression are formed. A part of patients with castrate-resistant prostate cancer has no metastases (according to standard imaging methods). The main goal of treatment of these patients is to prolong the time before metastasis formation. This article presents a review of the current understanding of the molecular mechanisms underlying the inhibition of androgen-receptor signaling with enzalutamide, a second-generation androgen receptor antagonist, and the results of clinical studies of its efficacy and safety in castrate-resistant prostate cancer without metastases. It was determined that enzalutamide stimulates the expression of a new class of genes that are not regulated by dihydrotestosterone. It was found that, in addition to inhibiting androgen receptors, enzalutamide can act as a partial transcriptional agonist. Enzalutamide therapy has been shown to reduce the risk of tumor progression and death in patients with non-metastatic castrate-resistant prostate cancer and is well tolerated. Treatment with this drug increases the time before metastases appear, before the first use of subsequent anti-tumor therapy is necessary, and the period before prostate-specific antigen levels have progressed. Study of mechanisms induced by enzalutamide – inhibition of prostate cancer cells growth and activation of genes contributing to cancer development by enzalutamide-related androgen receptor – can help to clarify possible ways of resistance formation to this drug and possibilities of its overcoming with combined therapy.

1. Alekseev B.Y., Nyushko K.M., Krasheninnikov A.A., Safronova E.Yu., Sergienko S.A., Kalpinskiy A.S. et al. Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment. Onkourologya = Cancer Urology. 2016;12(2):64–73. (In Russ.) doi: 10.17650/1726-9776-2016-12-2-64-73.

2. Kaprin A.D., Starinsky V.V., Petrova G.V. (eds.). The State of Cancer Care in Russia in 2018. Moscow: P.A. Herzen Moscow state medical research Institute – branch of the Federal state medical research CENTER of radiology of the Ministry of health of Russia; 2019. 236 p. (In Russ.) Available at: http://www.oncology.ru/service/statistics/condition/2018.pdf.

3. Cornford P., Bellmunt J., Bolla M., Briers E., De Santis M., Gross T. et al. EAUESTRO-SIOG guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–642. doi: 10.1016/j.eururo.2016.08.002.

4. Nuhn P., De Bono J.S., Fizazi K., Freedland S.J., Grilli M., Kantoff P.W. et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75(1):88–99. doi: 10.1016/j.eururo.2018.03.028.

5. Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N., Higano C.S. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433. doi: 10.1056/NEJMoa1405095.

6. Afshar M., Evison F., James N.D., Patel P. Shifting paradigms in the estima tion of survival for castration-resistant prostate cancer: a tertiary academic center experience. Urol Oncol. 2015;33(8):338.e1-7. doi: 10.1016/j.urolonc.2015.05.003.

7. Smith M.R., Cook R., Lee K.A., Nelson J.B. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011;117(10):2077–2085. doi: 10.1002/cncr.25762.

8. Smith M.R., Saad F., Oudard S., Shore N., Fizazi K., Sieber P. et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013;31(30):3800– 3806. doi: 10.1200/JCO.2012.44.6716.

9. Xie W., Regan M.M., Buyse M., Halabi S., Kantoff P.W., Sartor O. et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 2017;35(27):3097–3104. doi: 10.1200/JCO.2017.73.9987.

10. Lodde M., Lacombe L., Fradet Y. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. Urology. 2010;76(5):1189–1193. doi: 10.1016/j.urology.2009.12.057.

11. Suzuki H., Okihara K., Miyake H., Fujisawa M., Miyoshi S., Matsumoto T. et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol. 2008;180(3):921–927. doi: 10.1016/j.juro.2008.05.045.

12. Heidegger I., Brandt M.P., Heck M.M. Treatment of non-mestastatic castration resistant prostate cancer in 2020: What is the best? Urol Oncol. 2020;38(4):129–136. doi: 10.1016/j.urolonc.2019.11.007.

13. Culig Z., Bartsch G., Hobisch A. Antiandrogens in prostate cancer endocrine therapy. Curr Cancer Drug Targets. 2004;4(5):455–461. doi: 10.2174/1568009043332925.

14. Bambury R.M., Rathkopf D.E. Novel and next-generation androgen receptordirected therapies for prostate cancer: Beyond abiraterone and enzalutamide. Urol Oncol. 2016;34(8):348–355. doi: 10.1016/j.urolonc.2015.05.025.

15. Guerrero J., Alfaro I.E., Gómez F., Protter A.A., Bernales S. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013;73(12):1291–1305. doi: 10.1002/pros.22674.

16. Efstathiou E., Titus M., Wen S., Hoang A., Karlou M., Ashe R. et al. Molecular characterization of enzalutamide-treated bone metastatic castrationresistant prostate cancer. Eur Urol. 2015;67(1):53–60. doi: 10.1016/j.eururo.2014.05.005.

17. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–790. doi: 10.1126/science.1168175.

18. Leibowitz-Amit R., Joshua A.M. Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol. 2012;19(3 Suppl.):22–31. doi: 10.3747/ co.19.1281.

19. Zhang T., Zhu J., George D.J., Armstrong A.J. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Expert Opin Pharmacother. 2015;16(4):473–485. doi: 10.1517/14656566.2015.995090.

20. Yuan X., Cai C., Chen S., Chen S., Yu Z., Balk S.P. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. 2014;33(22):2815–2825. doi: 10.1038/onc.2013.235.

21. Watson P.A., Arora V.K., Sawyers C.L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701–711. doi: 10.1038/nrc4016.

22. Chen Z., Lan X., Thomas-Ahner J.M., Wu D., Liu X., Ye Z. et al. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. EMBO J. 2015;34(4):502–516. doi: 10.15252/embj.201490306.

23. Yuan F., Hankey W., Wu D., Wang H., Somarelli J., Armstrong A.J. et al. Molecular determinants for enzalutamide-induced transcription in prostate cancer. Nucleic Acids Res. 2019;47(19):10104–10114. doi: 10.1093/nar/gkz790.

24. Arora V.K., Schenkein E., Murali R., Subudhi S.K., Wongvipat J., Balbas M.D. et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155(6):1309–1322. doi: 10.1016/j.cell.2013.11.012.

25. Isikbay M., Otto K., Kregel S., Kach J., Cai Y., Vander Griend D.J. et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014;5(2):72–89. doi: 10.1007/s12672-014-0173-2.

26. Cramer S.L., Saha A., Liu J., Tadi S., Tiziani S., Yan W. et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nat Med. 2017;23(1):120–127. doi: 10.1038/nm.4232.

27. Ji X., Qian J., Rahman S.M.J., Siska P.J., Zou Y., Harris B.K. et al. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. Oncogene. 2018;37(36):5007–5019. doi: 10.1038/s41388-018-0307-z.

28. Alessandrini F., Pezze L., Ciribilli Y. LAMPs: Shedding light on cancer biology. Semin Oncol. 2017;44(4):239–253. doi: 10.1053/j.seminoncol.2017.10.013.

29. Penson D.F., Armstrong A.J., Concepcion R., Agarwal N., Olsson C., Karsh L. et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J Clin Oncol. 2016;34(18):2098–2106. doi: 10.1200/JCO.2015.64.9285.

30. Hussain M., Fizazi K., Saad F., Rathenborg P., Shore N., Ferreira U. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–2474. doi: 10.1056/NEJMoa1800536.